TDMS Study 88032-05 Pathology Tables
NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 27 WEEK SSAC Facility: Battelle Columbus Laboratory Chemical CAS #: 434-07-01 Lock Date: 01/02/96 Cage Range: All Reasons For Removal: 25017 Scheduled Sacrifice Removal Date Range: 10/21/93 - 10/22/93 Treatment Groups: Include 002 0 MG/KG Include 004 3 MG/KG Include 006 30 MG/KG Include 008 100 MG/KG Include 001 0 MG/KG Include 003 3 MG/KG Include 005 30 MG/KG Include 007 150 MG/KG a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 30 MG/KG 100 MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 90 90 90 90 Scheduled Sacrifice 10 10 10 10 Early Deaths Survivors Animals Examined Microscopically 10 10 10 10 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM None ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM None ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM None ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM None ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM None ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 30 MG/KG 100 MG/KG ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM None ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM None Page 3 NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150 MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 90 90 90 90 Scheduled Sacrifice 10 10 10 10 Early Deaths Survivors Animals Examined Microscopically 10 10 10 10 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM None ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM None ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Pituitary Gland (10) (10) (10) (10) Pars Distalis, Adenoma 1 (10%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM None ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM None ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150 MG/KG ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM None ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM None ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM None Page 5 NTP Experiment-Test: 88032-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC OXYMETHOLONE Date: 11/25/97 Route: GAVAGE Time: 07:12:49 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 30 MG/KG 150 MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 1 Total Primary Neoplasms 1 Total Animals with Benign Neoplasms 1 Total Benign Neoplasms 1 Total Animals with Malignant Neoplasms Total Malignant Neoplasms Total Animals with Metastatic Neoplasms Total Metastatic Neoplasm Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 6 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------